Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.


Journal Article (Review)

As our understanding of cancer pathophysiology has increased, so have the number of targeted therapeutic agents available. By targeting specific molecules involved in tumorigenesis, targeted therapeutic agents offer the potential for significant efficacy against tumor cells while minimizing the adverse effects. We highlight the recently recognized ophthalmic complications of targeted cancer therapy, as well as recently recognized complications of traditional chemotherapeutic agents.

Full Text

Cited Authors

  • Kheir, WJ; Sniegowski, MC; El-Sawy, T; Li, A; Esmaeli, B

Published Date

  • September 2014

Published In

Volume / Issue

  • 59 / 5

Start / End Page

  • 493 - 502

PubMed ID

  • 25130892

Pubmed Central ID

  • 25130892

Electronic International Standard Serial Number (EISSN)

  • 1879-3304

Digital Object Identifier (DOI)

  • 10.1016/j.survophthal.2014.02.004


  • eng

Conference Location

  • United States